Abbott Laboratories (ABT)
Healthcare · Medical - Devices · Data as of 2026-10-22
Bottom line
ABT is trading near its usual valuation, near its historical support zone, and recent volume suggests money flowing in. Historically, this combination has been a favourable starting point for further research. Past patterns are not a guarantee of future results.
Valuation — Trading near its usual range (Yellow)
ABT trades at 32× earnings, roughly in line with its own 5-year average of 33× and above similar healthcare companies we track (28×, 53 peers). That is roughly what the market has typically paid for this stock. Its free-cash-flow yield is about 5.0%. Its current multiple sits around the 64th percentile of its own last five years — toward the high end of its own range.
Price zones — Near its historical support zone (Green)
At $102.51, the stock is close to the lower end of its recent range. Over the past year ABT has traded between $81.97 and $132.03; its historical support zone sits near $102.33 and resistance near $105.32. It is above one of its moving averages and below the other — a mixed trend picture.
52-week range $81.97–$132.03 · 50-day average $105.32 · 200-day average $102.33
Money flow — Money is flowing in (Green)
Recent trading in ABT shows more volume on rising days than falling days, a pattern often described as accumulation. Volume on up days has been about 1.1× volume on down days over the last 30 sessions.
Dividends & company facts
ABT paid $2.52 a share in dividends over the past year — 2.5% of today's price — and has raised it in each of the last five years. It also bought back shares: $497 million in fiscal 2025, about 0.29% of its market value.
- Dividend yield (12 months)
- 2.46%
- Paid over 12 months
- $2.52 a share
- Payout ratio
- 78.5%
- Buybacks
- 0.29% (fiscal 2025)
- Shares, past year
- -0.5%
- Revenue, 12 months
- $46.6B
- Profit, 12 months
- $5.4B
- Employees
- 115,000
- CEO
- Robert Ford
- Headquarters
- Abbott Park, IL
- Listed since
- 1980 · NYSE
About the company
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm,…
Related stocks
一句话结论
ABT 估值接近其惯常水平，接近其历史支撑区，近期成交量显示资金正在流入。从历史来看，这样的组合是一个值得进一步研究的有利起点。过去的形态并不能保证未来的结果。
估值 — 处于其惯常的估值区间
ABT 目前的市盈率为 32×，大致持平于其自身 5 年平均的 33×，并且高于我们追踪的同类Healthcare公司（28×，53 家）。这大致就是市场以往为这只股票所付出的水平。其自由现金流收益率约为 5.0%。它当前的估值倍数大约位于自身过去五年分布的第 64 百分位——处于自身区间的偏高位置。
价格区间 — 接近其历史支撑区
目前价格为 $102.51，接近其近期区间的下沿。过去一年 ABT 的价格在 $81.97 到 $132.03 之间波动；其历史支撑区在 $102.33 附近，阻力区在 $105.32 附近。它位于其中一条均线上方、另一条下方——趋势信号并不一致。
资金流向 — 资金正在流入
ABT 近期上涨日的成交量高于下跌日，这种形态常被称为吸筹。过去 30 个交易日，上涨日的成交量约为下跌日的 1.1×。
股息与公司概况
ABT 过去一年每股派息 2.52 美元，相当于当前股价的 2.5%，过去五年每年都有上调。它也回购了股票：2025 财年回购 5.0亿美元，约占市值的 0.29%。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.